Avita Medical, Inc. · NASDAQ:RCEL
Avita Medical — Q1 2024 Earnings Presentation
7 slides from Avita Medical's earnings presentation, May 13, 2024
Slide 1: Q1 2024 Earnings Presentation
NASDAQ: RCEL ASX: AVH Q1 2024 Earnings Presentation May 13, 2024
Slide 2: Forward-Looking Statements & Legal Disclaimers
Forward-Looking Statements & Legal Disclaimers 2024.Q4 v9 This presentation and the accompanying oral commentary are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this pre
Slide 3: Strong Pipeline as of May 10, 2024
Strong Pipeline as of May 10, 2024* RECELL for Full-Thickness Skin Defects Value Analysis Committee (VAC) Submissions 178 Expecting Previously Announced Rejections Approvals in Q2 New Accounts 46 73 8 Targeting 700+ Trauma & Burn Centers (next 2-3 years) * From the launch of the full-thickness skin
Slide 4: RECELL GO Manufacturing is Ready
RECELL GO Manufacturing is Ready P4
Slide 5: Strategic Transformation – Continuum of Wound Care
Strategic Transformation – Continuum of Wound Care Continuum of Burn/Full-Thickness Skin Defect Wound Care Dermal Wound Bed Replacement/ Epidermal Wound Bed Hemostasis Dressings Preparation Scaffolds/ Skin Replacement Substitutes RECELL stimulates Exploration Actively exploring Actively exploring he
Slide 6: Product Compatibility for Wound Care
Product Compatibility for Wound Care Clinical Presentation: full-thickness skin defect with concern for infection Dressing optimized for protection and moisture PermeaDerm by Stedical management RECELL + meshed split- Robust closure using significantly less skin thickness skin graft compared to trad
Slide 7: Slide 7